Covid-19NCT04549636
COVID-19 Related Lung Ventilation and Perfusion Injury
An observational study of Covid-19 and Asthma, run by McMaster University at 1 site in Canada.
Trial summary
Little is currently known about the immediate and long-term effect of COVID-19 on lung ventilation (delivery of air to the lungs) and lung perfusion (delivery of blood to the lungs). Some people who survive COVID-19 may have lung ventilation and/or perfusion injury that persists following COVID-19 recovery. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- What is being tested?
- V/Q SPECT-CT, St. George's Respiratory Questionnaire (SGRQ) and mMRC (Modified Medical Research Council) Dyspnea Scale
- How many people
- 42 participants
- Where
- 1 siteCanada
- Study dates
- 18 Oct 2020to 26 Jan 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: community sample
Who may be able to join
- For all participants:
- Males and females ≥ 18 years of age
- Individuals able and willing to provide written informed consent
- Individuals able and willing to comply with the study protocol
- For participants with asthma:
- Individuals with physician confirmed asthma (12% bronchodilator reversibility or PC20 methacholine less than 8mg/ml)
Show all 10Show fewer
- Individuals treated with inhaled corticosteroids, oral corticosteroids and/or anti-T2 biologics
- For participants who recently recovered from covid-19:
- Individuals previously diagnosed with covid-19 confirmed by FLOQswab test
- Individuals who recently (≤4-weeks) recovered from covid-19
Who cannot join
- For all participants:
- Males and females < 18 years of age
- Individuals who are unable to read and/or understand English
- Individuals who are pregnant or breastfeeding
- Individuals who currently smoke or are an ex-smoker with ≥10 pack-year smoking history
- Individuals who in the opinion of the investigator, are mentally or legally incapacitated, preventing informed consent from being obtained
Show all 11Show fewer
- Individuals who are unable to complete one or more study manoeuvres
- For participants with no history of lung disease:
- Individuals with a history of respiratory infection or disease
- For participants who have not been diagnosed with covid-19:
- Individuals who have previously had covid-19 confirmed by FLOQswab test
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Longitudinal Study to Characterize and Understand the Clinical Relevance of SARS-CoV2 Related Ventilation and Perfusion Injury Evaluated by V/Q SPECT-CT in an Asthmatic and Healthy Population
Little is currently known about the immediate and long-term effect of COVID-19 on lung ventilation (delivery of air to the lungs) and lung perfusion (delivery of blood to the lungs). Some people who survive COVID-19 may have lung ventilation and/or perfusion injury that persists following COVID-19 recovery. This lung injury may be related to inflammation in the lung, breathlessness, exercise limitation and reduced quality of life. Therefore, towards the goal of understanding the effects of COVID-19 on lung health, the purpose of this study is to characterize and understand the clinical relevance of COVID-19 related lung ventilation and perfusion injury and associated inflammatory status, ≤4 weeks and 6-months following COVID-19 recovery in an asthmatic and healthy population. To do this, an asthmatic and healthy population who have, and have not, been previously diagnosed with COVID-19 will be studied.
- Being tested
- V/Q SPECT-CT, St. George's Respiratory Questionnaire (SGRQ), mMRC (Modified Medical Research Council) Dyspnea Scale, Six-minute walk test (6MWT), Spirometry
- Keywords
- covid-19, lung ventilation, lung perfusion, V/Q SPECT, lung health, Technegas
- Medical subject headings
- COVID-19, Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
V/Q SPECT-CTOther
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
St. George's Respiratory Questionnaire (SGRQ)Other
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
mMRC (Modified Medical Research Council) Dyspnea ScaleOther
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Six-minute walk test (6MWT)Other
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
SpirometryOther
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Plethysmography & DLCOOther
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Airwave OscillometryOther
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
| Study group | Role | What they receive |
|---|---|---|
| healthy COVID-19+ | Individuals who recently recovered from COVID-19 and who have no history of lung disease Receives: Other: V/Q SPECT-CT; Other: St. George's Respiratory Questionnaire (SGRQ); Other: mMRC (Modified Medical Research Council) Dyspnea Scale; Other: Six-minute walk test (6MWT); Other: Spirometry; Other: Plethysmography & DLCO; Other: Airwave Oscillometry | |
| asthmatic COVID-19+ | Individuals who recently recovered from COVID-19 and who have asthma Receives: Other: V/Q SPECT-CT; Other: St. George's Respiratory Questionnaire (SGRQ); Other: mMRC (Modified Medical Research Council) Dyspnea Scale; Other: Six-minute walk test (6MWT); Other: Spirometry; Other: Plethysmography & DLCO; Other: Airwave Oscillometry | |
| healthy COVID-19- | Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease Receives: Other: V/Q SPECT-CT; Other: St. George's Respiratory Questionnaire (SGRQ); Other: mMRC (Modified Medical Research Council) Dyspnea Scale; Other: Six-minute walk test (6MWT); Other: Spirometry; Other: Plethysmography & DLCO; Other: Airwave Oscillometry | |
| asthmatic COVID-19- | Individuals who have not been diagnosed with COVID-19 and who have asthma Receives: Other: V/Q SPECT-CT; Other: St. George's Respiratory Questionnaire (SGRQ); Other: mMRC (Modified Medical Research Council) Dyspnea Scale; Other: Six-minute walk test (6MWT); Other: Spirometry; Other: Plethysmography & DLCO; Other: Airwave Oscillometry |
What is being measured
The primary outcome is the main question the study is designed to answer.
Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy
The short-term difference in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy
The short-term difference in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Short-term difference in lung ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
The short-term difference in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy
The long-term difference in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy
The long-term difference in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
The long-term difference in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
The short-term difference in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
The short-term difference in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Short-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
The short-term difference in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
The long-term difference in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
The long-term difference in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
The long-term difference in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - healthy
Difference in the 6-month change in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - healthy
Difference in the 6-month change in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
Difference in the 6-month change in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Measured: 6-months post COVID-19 recovery (Visit 2)
Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
Difference in the 6-month change in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
Measured: 6-months post COVID-19 recovery (Visit 2)
Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
Difference in the 6-month change in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
Measured: 6-months post COVID-19 recovery (Visit 2)
Longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
Difference in the 6-month change in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
Measured: 6-months post COVID-19 recovery (Visit 2)
Secondary outcomes (8)
Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score ≤4-weeks post COVID-19 recovery
In COVID-19+ participants, the correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score ≤4-weeks post COVID-19 recovery (Visit 1).
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with six-minute walk distance (6MWD) ≤4-weeks post COVID-19 recovery
In COVID-19+ participants, the correlation of lung ventilation with six-minute walk distance (6MWD) ≤4-weeks post COVID-19 recovery (Visit 1).
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) ≤4-weeks post COVID-19 recovery
In COVID-19+ participants, the correlation of lung ventilation with the forced expiratory volume in one second (FEV1) ≤4-weeks post COVID-19 recovery (Visit 1).
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) ≤4-weeks post COVID-19 recovery
In COVID-19+ participants, the correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) ≤4-weeks post COVID-19 recovery (Visit 1).
Measured: ≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score 6-months post COVID-19 recovery
In COVID-19+ participants, the correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score 6-months post COVID-19 recovery (Visit 2).
Measured: 6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with six-minute walk distance (6MWD) 6-months post COVID-19 recovery
In COVID-19+ participants, the correlation of lung ventilation with six-minute walk distance (6MWD) 6-months post COVID-19 recovery (Visit 2).
Measured: 6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) 6-months post COVID-19 recovery
In COVID-19+ participants, the correlation of lung ventilation with the forced expiratory volume in one second (FEV1) 6-months post COVID-19 recovery (Visit 2).
Measured: 6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) 6-months post COVID-19 recovery
In COVID-19+ participants, the correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) 6-months post COVID-19 recovery (Visit 2).
Measured: 6-months post COVID-19 recovery (Visit 2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2020
- Study start18 Oct 2020
- Primary completion26 Jan 2022
- Study completion26 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid-19Studies of the same condition, open and under way.
- More trials run by McMaster UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- McMaster University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sarah Svenningsen, PhD, Principal investigator, McMaster University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04549636
- Sponsor's protocol ID
- FIRH002
- Status last verified
- Aug 2025
- First submitted
- 28 Aug 2020
- Last updated
- 14 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared with other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Longitudinal Study to Characterize and Understand the Clinical Relevance of SARS-CoV2 Related Ventilation and Perfusion Injury Evaluated by V/Q SPECT-CT in an Asthmatic and Healthy Population
- ClinicalTrials.gov ID
- NCT04549636
- Acronym / sponsor ID
- FIRH002
- Keywords
- covid-19, lung ventilation, lung perfusion, V/Q SPECT, lung health, Technegas
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- McMaster UniversityUniversity, hospital or other
- Study start
- 18 Oct 2020 (actual)
- Primary completion
- 26 Jan 2022 (actual)
- Study completion
- 26 Jan 2022 (actual)
- First posted
- 16 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Little is currently known about the immediate and long-term effect of COVID-19 on lung ventilation (delivery of air to the lungs) and lung perfusion (delivery of blood to the lungs). Some people who survive COVID-19 may have lung ventilation and/or perfusion injury that persists following COVID-19 recovery. This lung injury may be related to inflammation in the lung, breathlessness, exercise limitation and reduced quality of life. Therefore, towards the goal of understanding the effects of COVID-19 on lung health, the purpose of this study is to characterize and understand the clinical relevance of COVID-19 related lung ventilation and perfusion injury and associated inflammatory status, ≤4 weeks and 6-months following COVID-19 recovery in an asthmatic and healthy population. To do this, an asthmatic and healthy population who have, and have not, been previously diagnosed with COVID-19 will be studied.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| healthy COVID-19+ | – | Other: V/Q SPECT-CT, Other: St. George's Respiratory Questionnaire (SGRQ), Other: mMRC (Modified Medical Research Council) Dyspnea Scale, Other: Six-minute walk test (6MWT), Other: Spirometry, Other: Plethysmography & DLCO, Other: Airwave OscillometryIndividuals who recently recovered from COVID-19 and who have no history of lung disease |
| asthmatic COVID-19+ | – | Other: V/Q SPECT-CT, Other: St. George's Respiratory Questionnaire (SGRQ), Other: mMRC (Modified Medical Research Council) Dyspnea Scale, Other: Six-minute walk test (6MWT), Other: Spirometry, Other: Plethysmography & DLCO, Other: Airwave OscillometryIndividuals who recently recovered from COVID-19 and who have asthma |
| healthy COVID-19- | – | Other: V/Q SPECT-CT, Other: St. George's Respiratory Questionnaire (SGRQ), Other: mMRC (Modified Medical Research Council) Dyspnea Scale, Other: Six-minute walk test (6MWT), Other: Spirometry, Other: Plethysmography & DLCO, Other: Airwave OscillometryIndividuals who have not been diagnosed with COVID-19 and who have no history of lung disease |
| asthmatic COVID-19- | – | Other: V/Q SPECT-CT, Other: St. George's Respiratory Questionnaire (SGRQ), Other: mMRC (Modified Medical Research Council) Dyspnea Scale, Other: Six-minute walk test (6MWT), Other: Spirometry, Other: Plethysmography & DLCO, Other: Airwave OscillometryIndividuals who have not been diagnosed with COVID-19 and who have asthma |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- community sample
Key inclusion criteria (10 listed)
- Males and females ≥ 18 years of age
- Individuals able and willing to provide written informed consent
- Individuals able and willing to comply with the study protocol
- Individuals with physician confirmed asthma (12% bronchodilator reversibility or PC20 methacholine less than 8mg/ml)
- Individuals treated with inhaled corticosteroids, oral corticosteroids and/or anti-T2 biologics
Key exclusion criteria (11 listed)
- Males and females < 18 years of age
- Individuals who are unable to read and/or understand English
- Individuals who are pregnant or breastfeeding
- Individuals who currently smoke or are an ex-smoker with ≥10 pack-year smoking history
- Individuals who in the opinion of the investigator, are mentally or legally incapacitated, preventing informed consent from being obtained
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| V/Q SPECT-CTAt visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan. | Other | asthmatic COVID-19+, asthmatic COVID-19-, healthy COVID-19+, healthy COVID-19- |
| St. George's Respiratory Questionnaire (SGRQ)At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ). | Other | asthmatic COVID-19+, asthmatic COVID-19-, healthy COVID-19+, healthy COVID-19- |
| mMRC (Modified Medical Research Council) Dyspnea ScaleAt visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale. | Other | asthmatic COVID-19+, asthmatic COVID-19-, healthy COVID-19+, healthy COVID-19- |
| Six-minute walk test (6MWT)At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT). | Other | asthmatic COVID-19+, asthmatic COVID-19-, healthy COVID-19+, healthy COVID-19- |
| SpirometryAt visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC. | Other | asthmatic COVID-19+, asthmatic COVID-19-, healthy COVID-19+, healthy COVID-19- |
| Plethysmography & DLCOAt visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed. | Other | asthmatic COVID-19+, asthmatic COVID-19-, healthy COVID-19+, healthy COVID-19- |
| Airwave OscillometryAt visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X. | Other | asthmatic COVID-19+, asthmatic COVID-19-, healthy COVID-19+, healthy COVID-19- |
Primary outcome
Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Short-term difference in lung ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy
Time frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy
Time frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
Time frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Short-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
Time frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
Time frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
Time frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - healthy
Time frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - healthy
Time frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
Time frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
Time frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
Time frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
Longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
Time frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
8 secondary outcomes
Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score ≤4-weeks post COVID-19 recovery
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with six-minute walk distance (6MWD) ≤4-weeks post COVID-19 recovery
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) ≤4-weeks post COVID-19 recovery
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) ≤4-weeks post COVID-19 recovery
Time frame: ≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score 6-months post COVID-19 recovery
Time frame: 6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with six-minute walk distance (6MWD) 6-months post COVID-19 recovery
Time frame: 6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) 6-months post COVID-19 recovery
Time frame: 6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) 6-months post COVID-19 recovery
Time frame: 6-months post COVID-19 recovery (Visit 2)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2025.
- Individual participant dataSharing planned: No. IPD will not be shared with other researchers.
Related trials for Covid-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah Svenningsen, PhD principal investigator
McMaster University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid-19 and Asthma, run by McMaster University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy (time frame: ≤4-weeks post COVID-19 recovery (Visit 1)). The study lists 18 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2025.